There were differences in opinion between the SCMs and the HCPs regarding practical scenarios, such as GT for patients with BRCA germline pathogenic variants at the first diagnosis of BC (HCPs [47·8%] vs SCMs [100%]) and GT for patients with eTNBC (HCPs [37·3%] vs SCMs [93·8%]) and with HR+/HER2-negative eBC (HCPs [39·6%] vs SCMs [87·4%]) irrespective of age. This evidence concerns the gene ERBB2 and breast cancer.